Dr. Reddys Laboratories Limited v. Pro Bios Pharmaceuticals Pvt. Ltd.

In the pharmaceutical world, a brand name is more than a label — it is a promise of trust, quality, and patient safety. When a competitor copies not just the name but the very look of a medicine on the shelf, the stakes rise far beyond ordinary trademark disputes. The case of Dr. Reddy's Laboratories versus Pro Bios Pharmaceuticals is a striking example of how courts can move decisively when a brand's identity is brazenly cloned, and what it takes for a plaintiff to secure immediate relief.

Dr. Reddy's Laboratories Limited, a well-established pharmaceutical company, had built its reputation around the registered trademark 'OMEZ', used for its medicinal preparation OMEPRAZOLE. Through continuous and longstanding use, the brand had become a recognizable name in the market. Pro Bios Pharmaceuticals Pvt. Ltd., the defendant, entered the picture with a strikingly similar mark — 'OMZES' — for what appeared to be a comparable product. The similarity did not stop at the name. The defendant had also mimicked the packaging of Dr. Reddy's product, creating an overall impression that could easily mislead consumers at the pharmacy shelf. Faced with this unauthorized imitation, Dr. Reddy's approached the Delhi High Court seeking urgent intervention to protect its registered rights and prevent further damage to its brand.

Dr. Reddy's argued that it held a valid registration for the trademark 'OMEZ' and that the defendant's use of 'OMZES' constituted clear trademark infringement. The plaintiff emphasized that the similarity between the two marks was not merely phonetic but extended to the visual presentation of the product, including the packaging design. This dual layer of copying — both the mark and the trade dress — was presented as evidence of an intent to ride on the goodwill of the established brand and to create confusion among consumers, particularly at the point of purchase. The defendant, appearing to have offered no substantive counter at this stage, faced the weight of a registered right, established market presence, and demonstrable copying. The legal friction centered on whether the plaintiff had done enough to convince the court that immediate intervention was warranted before the defendant could be heard.

The Delhi High Court found that Dr. Reddy's had succeeded in establishing a prima facie case in its favor. The court recognized both the trademark infringement arising from the use of 'OMZES' and the copying of the plaintiff's packaging as serious concerns. Acknowledging that allowing the defendant to continue selling under these circumstances would cause irreparable loss to Dr. Reddy's, the court granted an ad interim ex-parte injunction. This meant that the defendant was immediately restrained from using the infringing mark and copied packaging, even before a full hearing on the merits could take place. The court's reasoning underscored the strength of registered trademark rights, the value of continuous use in building protectable goodwill, and the critical role of packaging similarity in establishing consumer confusion.

For founders and IP professionals in the pharmaceutical space, this case delivers a clear and actionable lesson: a registered trademark alone is powerful, but combining it with evidence of continuous use, established goodwill, and demonstrable consumer confusion — including through packaging similarity — dramatically strengthens the case for urgent relief. When a competitor copies not just your name but your entire visual identity, do not wait. Move quickly, present a complete picture of your rights and the imitation, and the courts can act decisively to protect your brand before the damage becomes irreversible.